
Opinion|Videos|February 5, 2024
Bispecific Therapies: Current and Future Considerations
With their closing thoughts, the panelists provide their key takeaways from this discussion surrounding the operationalization of bispecifics.
Advertisement
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NYC Nurses Strike Enters Day 5 Amid Staffing, Safety, and Benefit Disputes
2
Long-term CR Seen With Allo-CAR-NK Cell Therapy Plus Rituximab in Waldenstrom NHL
3
CheckMate 9LA at 6 Years Shows Enduring Benefits From Dual Immunotherapy Plus Chemotherapy in Metastatic NSCLC
4
France Expands BOT–BAL Immunotherapy Access for Ovarian Cancer and Soft Tissue Sarcoma
5





























































